A short explainer on the challenge of getting peptides past the gut intact so they can act on specific targets when taken by mouth.
Recap by typeshit. Post by Facebook on Facebook.
A retrospective study in Cureus looks back at how well once-weekly semaglutide worked, and how safe it was, for teenagers with obesity.
Presented at Sleep Europe 2026, both trials found retatrutide lowered the apnea-hypopnea index more than placebo, including in people with type 2 diabetes.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
At a Pretoria roundtable, industry groups pushed police to act. SAHPRA says it has seized products, opened criminal cases and raided a compounding site in Silverton.
A short report on liraglutide, an older GLP-1 drug, and its weight loss effect. Few details come with it, and the finding is not new.
Loading…